Peptides against Mac-1 do not sufficiently target leukemia or lymphoma in vivo

Anticancer Research

Volumn 34, Issue 2, 2014, Pages 645-650

  Suojanen, Juho ^a,b,c,d   Reunanen, Justus ^a,e   Ranta, Tanja Maria ^a   Peñate Medina, Oula ^f   Salo, Tuula ^c,d   Saris, P E R ^a   Sorsa, Timo ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Institute of Dentistry   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e Dept of Basic Veterinary Science   (Finland)

^f UNIVERSITY OF KIEL   (Germany)

Author keywords

Bioactive peptide; Green fluorescent protein; Leukemia; Lymphoma; Mac 1; Xenograft; M 2 integrin

Indexed keywords

GREEN FLUORESCENT PROTEIN; MACROPHAGE 1 ANTIGEN INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; BIOACTIVE PEPTIDE; CD11B ANTIGEN; HYBRID PROTEIN; PEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MOTION; CONTROLLED STUDY; DRUG TARGETING; HISTIOCYTIC LYMPHOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; TUMOR CELL INOCULATION; AMINO ACID SEQUENCE; ANIMAL; CELL STRAIN U937; DRUG SCREENING; FEMALE; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOMA; MAC-1; METABOLISM; MOLECULAR GENETICS; NUDE MOUSE; PATHOLOGY; XENOGRAFT; ΑMΒ2 INTEGRIN;

BIOACTIVE PEPTIDE; GREEN FLUORESCENT PROTEIN; LEUKEMIA; LYMPHOMA; MAC-1; XENOGRAFT; ΑMΒ2 INTEGRIN;

AMINO ACID SEQUENCE; ANIMALS; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGE-1 ANTIGEN; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; PEPTIDES; RECOMBINANT FUSION PROTEINS; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897075643     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pitot HC: Fundamentals of Oncology, Fourth edition. Marcel Dekker pp. 378-391, 2002.
2. Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell 110: 673-687, 2002.
3. 2-Integrins and their cellular ligands. Eur J Biochem 245: 215-232, 1997.
4. Takada Y, Ye X and Simon S: The Integrins. Genome Biol 8: 215, 2007.
5. Vedder NB and Harlan JM: Increased surface expression of CD11b/CD18 (Mac-1) in not required for stimulated neutrofil adherence to cultured endothelium. J Clin Invest 81: 676-682, 1988.
6. Simon SI and Green CE: Molecular mechanics and dynamics of leukocyte recruitment during inflammation. Annu Rev Biomed Eng 7: 151-185, 2005.
7. Kinashi T: Intracellular signalling controlling Integrin activation in lymphocytes. Nature Rev Immunol 5: 546-549, 2005.
8. Weitz-Schmidt G, Welzenbach K, Brinkman V, Kamata T, Kallen JBruns C, Cottens S,Takada Y and Hommel U: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory Integrin site. Nature Med 7(6): 687-692, 2001.
9. 2 Integrin-mediated leukocyte cell adhesion by leucine-leucineglycine motif-containing peptides. J Cell Biol 153: 905-915, 2001.
10. Stefanidakis M, Björklund M, Ihanus E, Gahmberg CG and Koivunen E: Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 Integrins. J Biol Chem 278(36): 34674-34684, 2003.
11. 2 Integrin and promatrix metallo-proteinase-9 progelatinase in neurophils. J Immunol 172: 7060-7068, 2004.
12. 2 Integrin by a small molecule inhibits leukocyte migration and recruitment. Biochemistry 45: 2862-2871, 2006.
13. Suojanen J, Salo T, Sorsa T and Koivunen E: AlphaMbeta2 Integrin modulator exerts antitumor activity in vivo. Anticancer Res 27: 3775-3781, 2007.
14. Park JY, Arnaout MA and Gupta V: A simple, no-wash cell adhesion-based high-throughput assay for the discovery of small-molecule regulators of the Integrin CD11b/CD18. J Biomol Screen 12: 406-417, 2007.
15. Stefanidakis M, Karjalainen K, Jaalouk DE, Cahmberg CG, O'Brien S, Pasqualini R, Arap W and Koivunen E: Role of leukemia cell invadosome in extramedullary infiltration. Blood 114: 2008-2017, 2009.
16. Fagerholm SC, Hilden TJ, Nurmi SM and Gahmberg CG: Spesific alpha and beta chain phosphorylations regulate LFA-1 activation through affinity-dependent and -independent mechanisms. J Cell Biol 171(4): 705-715, 2005.
17. 2-Integrin binding peptide. Mol Diagn Ther (Epub Ahead of Pint)
18. Reunanen J, Ranta T-M, Penate-Medina O, Suojanen J, Sorsa T, Salo T, Koivunen E and Saris PEJ: A chimera of green fluorescent protein with gelatinase binding and tumor targeting peptide. Protein Expr Purif 72(2): 234-237, 2010.
19. Suojanen J, Vilen S-T, Nyberg P, Heikkilä P, Penate-Medina O, Saris PEJ, Hagström J, Ranta T-M, Salo T, Sorsa T and Reunanen J. Selective gelatinase inhibitor peptide is effective in targeting tongue carcinoma cell tumors in vivo. Anticancer Res 31(11): 3659-3664, 2011.
20. Heikkilä P, Suojanen J, Pirila E, Väänänen A, Koivunen E, Sorsa T and Salo T: Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. Int J Cancer 118: 2202-2209, 2006.
21. Lu H, Smith CW, Perrard J, Bullard D, Tang L, Shappel SB, Entman ML, Beaudet AL and Ballantyne CM: LFA-1 is sufficient in mediating neutrophil emigration in Mac-1-deficient mice. J Clin Invest 99: 1340-1350, 1997.
22. Bansal VS, Vaidya S, Somers EP, Kanuga M, Shevell D, Weikel R and Detmers PA: Small molecule antagonist of complement receptor type 3 block adhesion and adhesion-dependent oxidative burst in human polymorphonuclear leukocytes. J Pharm Exp Ther 304: 1016-1024, 2003.
23. Welzenbach K, Hommel U and Weitz-Schmidt G: Small molecule inhibitors induce conformational changes in the I domain of lymphopcyte function associated antigen-1. Molecular insights on Integrin inhibition. J Biol Chem 277: 10590-10598, 2002.
24. Park EJ, Peixoto A, Imai Y, Goodarzi A, Cheng G, Carman CV, von Andrian UH and Shimaoka M: Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymp nodes. Blood 115(8): 1572-1581, 2010.
25. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkilä P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E and Pasqualini R: Tumor targeting with a selective gelatinase inhibitor. Nat Biot 17: 768-774, 1999.
26. Suojanen J, Salo T, Koivunen E, Sorsa T and Pirilä E: A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol Ther 8: 2362-2370, 2009.
27. Laakkonen P, Zhang L and Ruoslahti E: Peptide targeting of tumor lymph vessels. Ann NY Acad Sci 1131: 37-43, 2008.